Polish Experts’ Position Statement on the use of granulocyte colony-stimulating factor in the treatment of chronic lymphocytic leukemia with venetoclax combined with rituximab
Hematology in Clinical Practice · 2021
DOI: 10.5603/hcp.2021.0008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2021. Verfasst von Elżbieta Iskierka-Jażdżewska und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia in Western countries. Venetoclax, a BCL-2 inhibitor, in combination with rituximab is an effective therapeutic option approved for the treatment of refractory and relapsed CLL. Neutropenia diagnosed before or during the above-mentioned therapy is a significant clinical problem, which often involves the need to reduce the dose or temporarily discontinue venetoclax in the initial period of therapy. In Experts’ opinion, the use of granulocyte colony-stimulating factor (G-CSF) during venetoclaxrituximab combined therapy is reasonable in patients with baseline neutrocyte count < 1000–500/mm3 and with high-risk neutropenia. The second important group for the use of G-CSF are patients developing grade 3 asymptomatic neutropenia during venetoclax dose escalation. Using G-CSF can prevent episodes that affect the maintenance of the venetoclax dose intensity and treatment continuity.
Zitieren
APA
Iskierka-Jażdżewska, E., Giannopoulos, K., Grosicki, S., Jamroziak, K., Wróbel, T., Zaucha, J. M., Dudziński, M., Bołkuń, Ł., Bodzenta, E., Drozd-Sokołowska, J., Samborska, A., Wolska-Washer, A., & Hus, I. (2021). Polish Experts’ Position Statement on the use of granulocyte colony-stimulating factor in the treatment of chronic lymphocytic leukemia with venetoclax combined with rituximab. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2021.0008
Vancouver
Iskierka-Jażdżewska E, Giannopoulos K, Grosicki S, Jamroziak K, Wróbel T, Zaucha JM, et al. Polish Experts’ Position Statement on the use of granulocyte colony-stimulating factor in the treatment of chronic lymphocytic leukemia with venetoclax combined with rituximab. Hematology in Clinical Practice. 2021. doi:10.5603/hcp.2021.0008
BibTeX
@article{IskierkaJadewska2021,
author = {Iskierka-Jażdżewska, Elżbieta and Giannopoulos, Krzysztof and Grosicki, Sebastian and Jamroziak, Krzysztof and Wróbel, Tomasz and Zaucha, Jan Maciej and Dudziński, Marek and Bołkuń, Łukasz and Bodzenta, Ewa and Drozd-Sokołowska, Joanna and Samborska, Agnieszka and Wolska-Washer, Anna and Hus, Iwona},
title = {Polish Experts’ Position Statement on the use of granulocyte colony-stimulating factor in the treatment of chronic lymphocytic leukemia with venetoclax combined with rituximab},
journal = {Hematology in Clinical Practice},
year = {2021},
doi = {10.5603/hcp.2021.0008}
}
EUVIMED